| Gene |
[ASCL1](/genes/ascl1) |
| UniProt |
P50553 |
| PDB |
2OP2, 5IV4 |
| Mol. Weight |
26.8 kDa |
| Localization |
Nucleus |
| Family |
bHLH transcription factor family |
| Diseases |
[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), Neuroblastoma |
is a protein that ascl1 plays critical roles in:. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
ASCL1 (Achaete-Scute Homolog 1), also known as MASH1, is a basic helix-loop-helix (bHLH) transcription factor. The protein contains:
- Basic region: Approximately 60 amino acids responsible for DNA binding, recognizing the E-box consensus sequence (CANNTG)
- HLH domain: Two amphipathic α-helices connected by a loop, mediating dimerization with other bHLH proteins
- Transactivation domain: Located at the N-terminus
ASCL1 typically forms heterodimers with ubiquitous bHLH proteins like E2A (TCF3) or HEB (TCF12) to bind DNA and regulate transcription.
ASCL1 plays critical roles in:
- Neurogenesis: Essential for neural progenitor cell specification and neuronal differentiation
- Dopaminergic Neuron Development: Critical for specification of dopaminergic neuron progenitors in the ventral mesencephalon
- Autonomic Nervous System Development: Essential for development of autonomic neurons
- Olfactory System: Regulates olfactory receptor neuron development
- Cell Cycle Regulation: Controls cell cycle exit during neuronal differentiation
ASCL1 acts as a transcriptional activator and repressor, regulating genes involved in neurogenesis, synaptic function, and neurotransmitter synthesis.
ASCL1 is implicated in several neurodegenerative processes:
- ASCL1 expression is reduced in AD brains
- Dysregulation of ASCL1 affects neuronal differentiation and plasticity
- May contribute to impaired adult neurogenesis in AD
- Links to APP processing and amyloid pathology
- Critical for dopaminergic neuron development and maintenance
- ASCL1+ progenitors can generate dopaminergic neurons for transplantation
- Gene therapy approaches using ASCL1 for PD treatment
- Protects dopaminergic neurons from oxidative stress
- ASCL1 is a key transcription factor for induced neuronal (iN) cell conversion
- Overexpression of ASCL1 can convert astrocytes into functional neurons
- Used in combination with other factors (e.g., BRN2, MYT1L) for neuronal reprogramming
- ASCL1-expressing neural progenitors show promise for cell replacement therapy
- ASCL1 is overexpressed in neuroblastoma and small cell lung cancer
- Acts as an oncogene in certain neural crest-derived tumors
ASCL1 is being explored as a therapeutic target:
- Cell Replacement Therapy: ASCL1+ neural progenitors for transplantation in PD and AD
- Direct Reprogramming: ASCL1-mediated conversion of glial cells into neurons
- iN Cell Generation: ASCL1 with other factors (BRN2, MYT1L, NEUROD1) for neuronal reprogramming
- Gene Therapy: Modulating ASCL1 expression to promote neurogenesis
- Lee et al. (2010). ASCL1 is a lineage oncogene controlling neural stem cell properties and medulloblastoma formation. Nature
- Kim et al. (2011). Direct reprogramming of fibroblasts to functional neurons by defined factors. Nature
- Pfisterer et al. (2011). Direct conversion of fibroblasts to stably induced neuronal cells. Proceedings of the National Academy of Sciences